Advertisement

Indian Journal of Clinical Biochemistry

, Volume 34, Issue 1, pp 95–100 | Cite as

Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders

  • Elif AzarsizEmail author
  • Gamze Eman
  • Sanem Eren Akarcan
  • Ezgi Ulusoy Severcan
  • Neslihan Karaca
  • Guzide Aksu
  • Necil Kutukculer
Original Research Article
  • 35 Downloads

Abstract

Anti-beta-2-glycoprotein I antibodies (anti-β2GPI) which are the main antiphospholipid antibodies that characterize the autoimmune “antiphospholipid syndrome” are pathogenic and are contributing to thrombosis. We aimed to evaluate the presence and the diagnostic importance of these antibodies in children with different rheumatologic diseases with or without thrombosis risk. A total of 100 children with different rheumatologic diseases evaluated retrospectively. The mean anti-β2GPI IgG (p = 0.108), IgA (p = 0.547), and IgM (p = 0.807) levels showed no statistically significant difference between different diagnosis groups. But anti-β2GPI IgA and IgM levels were higher in SLE patient group. The mean anti-β2GPI IgG (p = 0.375), IgA (p = 0.811), and IgM (p = 0.276) levels were not also showed difference between disease groups with/without predisposition to thrombosis even though concentrations were higher in thrombosis group. In children with rheumatological complaints, anti-β2GPI antibody measurements should not be the first diagnostic criteria if vasculitis is not thought as the primary defect underlying the clinical symptoms.

Keywords

Anti-β2GPI Autoimmunity Rheumatological disorder Thrombosis 

Notes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not—for—profit sectors.

Compliance with ethical standards

Conflict of interest

The Authors declared that they have no conflict of interests.

References

  1. 1.
    Groot PG, Meijers JC. β(2)-Glycoprotein I: evolution, structure, and function. J Thromb Haemost. 2011;9(7):1275–84.CrossRefGoogle Scholar
  2. 2.
    Nalli C, Piantoni S, Andreoli L, Motta M, Tincani A. Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin. Isr Med Assoc J. 2012;14(5):310–2.PubMedGoogle Scholar
  3. 3.
    Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 1985;66(5):1086–91.PubMedGoogle Scholar
  4. 4.
    Rioche M, Masseyeff R. Synthesis of plasma beta 2 glycoprotein I by human hepatoma cells in tissue culture. Biomedicine. 1974;21:420–3.PubMedGoogle Scholar
  5. 5.
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci. 1990;87:4120–4.CrossRefGoogle Scholar
  6. 6.
    Miyakis S, Lockshin MD, Atsumi M, Branch DW, Brey RL, Cervera R. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefGoogle Scholar
  7. 7.
    Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res. 1991;61(3):291–9.CrossRefGoogle Scholar
  8. 8.
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, et al. The “primary” antiphospholipid syndrome; major clinical and serological features. Medicine. 1989;68:366–74.CrossRefGoogle Scholar
  9. 9.
    Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the anticardiolipin syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine. 1989;68:353–65.CrossRefGoogle Scholar
  10. 10.
    Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627–33.CrossRefGoogle Scholar
  11. 11.
    Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 2012;64:1–10.CrossRefGoogle Scholar
  12. 12.
    de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.CrossRefGoogle Scholar
  13. 13.
    Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. 1990;20(3):231–6.CrossRefGoogle Scholar
  14. 14.
    Groot PG, Urbanus RT. The significance of autoantibodies against b2-glycoprotein I. Blood. 2012;120:266–74.CrossRefGoogle Scholar
  15. 15.
    Avcin T, Ambrozic A, Kuhar M, Kveder T, Rozman B. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology. 2001;40(5):565–73.CrossRefGoogle Scholar
  16. 16.
    Asherson RA, Cervera R. Antiphospholipid antibodies, and infections. Ann Rheum Dis. 2003;62:388–93.CrossRefGoogle Scholar
  17. 17.
    Sene D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome, and infections. Autoimmun Rev. 2008;7(4):272–7.CrossRefGoogle Scholar
  18. 18.
    Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109(6):797–804.CrossRefGoogle Scholar
  19. 19.
    Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black south African patients with infectious disease. Ann Rheum Dis. 2003;62:1106–11.CrossRefGoogle Scholar
  20. 20.
    Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, et al. IgA anti- B2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol. 2008;28:501–11.CrossRefGoogle Scholar
  21. 21.
    Mankai A, Achour A, Thabet Y, Manoubia W, Sakly W, Ghedira I. Anticardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease. Pathol Biol. 2012;60:291–5.CrossRefGoogle Scholar
  22. 22.
    Borges RB, Bodanese LC, Muhlen CA, Repetto G, Viehe M, Norman GL, et al. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arq Bras Cardiol. 2011;96:272–6.CrossRefGoogle Scholar
  23. 23.
    Serrano A, Garcia F, Serrano M, Ramirez E, Alfaro FJ, Lora D, et al. IgA antibodies against beta2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int. 2012;81:1239–44.CrossRefGoogle Scholar
  24. 24.
    Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114:593–5.CrossRefGoogle Scholar
  25. 25.
    Tubach F, Hayem G, Marchand JL, Weber M, Palazzo E, de Bandt M, et al. IgG anti-beta-2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol. 2000;27:1437–43.PubMedGoogle Scholar
  26. 26.
    Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost. 1991;66:520–4.CrossRefGoogle Scholar
  27. 27.
    Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol. 1991;10:289–93.CrossRefGoogle Scholar
  28. 28.
    Gupta R, Thabah MM, Gupta S, Shankar S, Kumar A. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int. 2009;30:277–9.CrossRefGoogle Scholar
  29. 29.
    Pasoto SG, Chakkour HP, Natalino RR, Viana VS, Bueno C, Lianza AC, et al. Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren’s syndrome. Clin Rheumatol. 2012;31:1331–8.CrossRefGoogle Scholar
  30. 30.
    Olech E, Merrill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006;8(2):100–8.CrossRefGoogle Scholar
  31. 31.
    Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122:e1100–7.CrossRefGoogle Scholar
  32. 32.
    Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol. 2011;38:450–3.CrossRefGoogle Scholar
  33. 33.
    Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS ONE. 2010;5(8):e12280.CrossRefGoogle Scholar
  34. 34.
    de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood. 2009;114:3656–61.CrossRefGoogle Scholar
  35. 35.
    Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallstrom T, et al. Beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118:2774–83.CrossRefGoogle Scholar
  36. 36.
    Lin F, Murphy R, White B, Kelly J, Feighery C, Doyle R, et al. Circulating levels of b2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006;15:87–93.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2017

Authors and Affiliations

  1. 1.Department of Pediatric Immunology, Faculty of MedicineEge UniversityBornova, IzmirTurkey

Personalised recommendations